FDA Natural Family Planning Curricula Background Material

The FDA has posted background material related to Natural Family Planning curricula. This notice provides informational resources for interested parties.

FDA Complaint for Public Comment

The FDA has posted a complaint for public comment, with the comment period closing on March 13, 2026. The complaint was authored by the CTP and is available for download.

FDA Document Details

The Food and Drug Administration (FDA) has published details for a new document on regulations.gov. This notice provides access to the document and its associated information for interested parties. Further details regarding the document's content are available via the provided URL.

FDA Complaint Document

The FDA has posted a complaint document related to FDA-2026-H-2387-0001. The document is authored by CTP and is available for download. This indicates a new enforcement action or investigation has been initiated.

FDA Acknowledgment Letter to Special FX Rentals

The FDA's Center for Devices and Radiological Health (CDRH) has issued an acknowledgment letter to Special FX Rentals. This notice confirms receipt of documentation and does not indicate approval or disapproval of any submissions.

FDA Variance Approval Letter

The FDA has issued a variance approval letter to Richard Lathrop, authored by CDRH. The letter, which contains restricted personally identifiable information, has been redacted and is available for download.

FDA Document - Copyrighted Content

The FDA has posted a document containing copyrighted content, identified by the docket number FDA-2026-P-2640-0004. The content itself is restricted due to copyright. This notice serves to inform the public of the document's availability and its restricted nature.

FDA Approves Labeling for RS, ANDA 202682

The U.S. Food and Drug Administration (FDA) has approved labeling for RS, as indicated by ANDA 202682. This approval was posted on March 13, 2026, and pertains to specific drug product labeling.

FDA Acknowledgment Letter to Athyna Pharma

The FDA's Center for Drug Evaluation and Research (CDER) has issued an acknowledgment letter to Athyna Pharma, LLC. This notice confirms receipt of a submission from the company.

FDA Approves Labeling for RLD, NDA N021411

The FDA has approved labeling for RLD (Reference Listed Drug) and NDA (New Drug Application) N021411. This notice indicates a regulatory action related to drug approval and labeling requirements.